Introduction Tulane University, founded in 1834, stands as a prestigious and highly selective independent research university in the United States. With its inclusion in the Association of American Universities, Tulane University distinguishes itself among an elite aggregation of institutions celebrated for outstanding graduate and professional education programs, as well as scholarly research. The university's array of schools and colleges provides undergraduate, graduate, and professional degrees across a multitude of disciplines, encompassing liberal arts, science and engineering, architecture, business, law, social work, medicine, public health, and tropical medicine.
Research endeavors at Tulane University have been bolstered by the creation of various centers, including the Newcomb College Institute, the Roger Thayer Stone Center for Latin American Studies, the Middle American Research Institute, the Tulane/Xavier Center for Bioenvironmental Research, the Murphy Institute, the Payson Center for International Development, the Tulane Cancer Center, the Tulane Center for Gene Therapy, and the Newcomb College Center for Research on Women. The Carnegie Foundation for the Advancement of Teaching has classified the university as one with "very high research activity," a renowned categorization reserved for only 2% of universities across the nation, based on an evaluation of over 4,300 higher education institutions. |
Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Infectious Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Neural stem cell therapy | 1 |
Synthetic peptide | 1 |
Small molecule drug | 1 |
Fusion protein | 1 |
Target- |
Mechanism Dopaminergic cell replacements [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAP2K5 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism μ opioid receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date04 Apr 2022 |
Sponsor / Collaborator |
Start Date01 Jun 2021 |
Sponsor / Collaborator |
Start Date01 Jul 2014 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SC-1-151 (Duquesne University) ( MAP2K5 x MEK1 x MEK2 ) | Triple Negative Breast Cancer More | Preclinical |
MDR504 hACE2-Fc ( ACE2 ) | COVID-19 More | Preclinical |
ZH-853 ( μ opioid receptor ) | Pain More | Preclinical |
ISC hpNSC(Duke University/International Stem Cell) | Stroke More | Preclinical |
PACAP-38 ( AC ) | Non-Small Cell Lung Cancer More | Discontinued |